Disc Medicine, Inc.
IRON · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.78 | -0.15 | -2.97 | -1.59 |
| FCF Yield | -2.06% | -2.59% | -2.55% | -1.48% |
| EV / EBITDA | -36.18 | -32.44 | -47.27 | -130.97 |
| Quality | ||||
| ROIC | -11.20% | -9.52% | -5.78% | -7.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.87 | 1.21 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.27% | -13.56% | -50.69% | -61.48% |
| Safety | ||||
| Net Debt / EBITDA | 1.79 | 1.78 | 2.78 | 12.26 |
| Interest Coverage | -73.82 | -67.48 | -44.53 | -60.40 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -7,518.62 | 0.00 | 0.00 | -79,480.00 |